Fifth Annual MDA Omaha Golf Classic Aims to Raise $175k for Muscular...
The fifth annual Muscular Dystrophy Association (MDA) of Omaha Golf Classic, sponsored by Meridian Clinical Research, is returning to Tiburon Golf Club on September 14. This year’s sold-out event will...(PRWeb September 06, 2022)Read the full story at https://www.prweb.com/releases/fifth_annual_mda_omaha_golf_classic_aims_to_raise_175k_for_muscular_dystrophy_research/prweb18881318.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 6, 2022 Category: Pharmaceuticals Source Type: news
Vamorolone Effective, Safe for Boys With Duchenne Muscular Dystrophy
THURSDAY, Sept. 1, 2022 -- For boys with Duchenne muscular dystrophy (DMD), vamorolone, a structurally unique dissociative steroidal anti-inflammatory drug, is effective and safe over a 24-week period, according to a study published online Aug. 29... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2022 Category: Pharmaceuticals Source Type: news
Novel Corticosteroid Shows Benefits in Boys With Duchenne Muscular Dystrophy
(MedPage Today) -- The novel corticosteroid vamorolone was effective and safe in the short-term treatment of boys with Duchenne muscular dystrophy (DMD), with no stunting of growth or negative effects on bone biomarkers, according to a pivotal... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - August 29, 2022 Category: Neurology Source Type: news
The people making a difference: the powerchair football coach leading his team to victory
Chris Hammans started coaching the side after his son Lewis took up the sport. Now, after Lewis ’s death, Chris is determined to continueChris Hammans ’ son Lewis was football-mad. He got it from his father. The two were close. “He was my best mate,” says Hammans, a 52-year-old pharmaceutical production manager from Haywards Heath.Lewis was diagnosed with muscular dystrophy, a genetic disorder that causes muscles to weaken over time, at the age of four. “He didn’t have the mobility other children in his nursery had,” says Hammans.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 15, 2022 Category: Science Authors: Sirin Kale Tags: Life and style Sport Football Medical research Genetics Science Family Source Type: news
Roche to present scientific progress across Alzheimer ’s disease pharmaceutical and diagnostic portfolio at 2022 AAIC Annual Meeting
Overview of two decades of research to be presented, including development ofgantenerumabDetailed results from phase II study evaluatingcrenezumab in autosomal dominant Alzheimer ' s diseaseData around biomarker selection for theElecsys Amyloid Plasma Panel, a blood-based biomarker test to aid in the detection of people with amyloid pathology, recently granted FDA Breakthrough Device DesignationBasel, 28 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data from 41 abstracts across its portfolio of Alzheimer ’s disease pharmaceuticals and diagnostics will be presented at the 2022 Alzheimer’s Associat...
Source: Roche Media News - July 28, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follic...
Source: Roche Media News - July 21, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andT...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news
Sarepta Therapeutics ’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
Dear Investor,Please find attached a press release by Sarepta Therapeutics regarding our partnered DMD asset:https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-investigational-gene-therapy-srp-9001Do not hesitate to contact us for any further questions.With best regards, Roche Investor Relations Dr. Bruno EschliPhone: +41 61 68-75284e-mail:bruno.eschli@roche.com Dr. Sabine Borngr äberPhone: +41 61 68-88027e-mail:sabine.borngraeber@roche.com Dr. Birgit MasjostPhone: +41 61 68-84814e-mail:birgit.masjost@roche.comDr. Gerard TobinPhone: +41 61 68-72942e-mail:gerard.tobin@roche.c...
Source: Roche Investor Update - July 6, 2022 Category: Pharmaceuticals Source Type: news
The Petri Dish: Sarepta hit with clinical hold, Decibel stock soars
The FDA has placed a clinical hold on a Duchenne muscular dystrophy drug made by Sarepta Therapeutics Inc. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 30, 2022 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
Roche provides update on Alzheimer ’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease
Crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer ’s diseaseFor more than a decade Roche has been working in collaboration with Banner Alzheimer ’s Institute, the University of Antioquia in Colombia and the National Institute on Aging on this pioneering prevention studyInitial data will be presented at the upcoming Alzheimer ' s Association International ConferenceBasel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimer ’s Institute, today announced results from the Alzheimer’s Prevention Initiative (API...
Source: Roche Media News - June 16, 2022 Category: Pharmaceuticals Source Type: news
Human Longevity offers AMRA BCP Scan to its members
Swedish image analysis software developer AMRA Medical has signed a definitiv...Read more on AuntMinnie.comRelated Reading:
AMRA gets U.S., Canadian clearance for MRI-based body composition scan
AMRA Medical gets FDA clearance for MasS Scan
Canada greenlights distribution of AMRA's muscle scan
AMRA touts liver MRI research at AASLD show
AMRA joins clinical trial on muscular dystrophy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 14, 2022 Category: Radiology Source Type: news
Code Biotherapeutics expects to double in size after raising $75M to advance gene therapy candidates
The company's first two targets are Duchenne muscular dystrophy and type 1 diabetes. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 7, 2022 Category: Pharmaceuticals Authors: John George Source Type: news
FDA approves Roche ’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walkPrescribing information updated with FIREFISH data showing the majority of symptomatic babies treated withEvrysdi for at least two years could sit for at least five secondsEvrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to dateBasel, 31 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under...
Source: Roche Media News - May 31, 2022 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walkPrescribing information updated with FIREFISH data showing the majority of symptomatic babies treated withEvrysdi for at least two years could sit for at least five secondsEvrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to dateBasel, 31 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under...
Source: Roche Investor Update - May 31, 2022 Category: Pharmaceuticals Source Type: news
Five New Neurology Studies: Possible Breakthroughs, Some Failures Five New Neurology Studies: Possible Breakthroughs, Some Failures
Dr Christoph Diener on promising early results in muscular dystrophy and Creutzfeldt-Jakob disease, and discouraging ones for aducanumab.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 9, 2022 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
